These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34453076)

  • 1. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
    Corné J; Le Du F; Quillien V; Godey F; Robert L; Bourien H; Brunot A; Crouzet L; Perrin C; Lefeuvre-Plesse C; Diéras V; De la Motte Rouge T
    Sci Rep; 2021 Aug; 11(1):17316. PubMed ID: 34453076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of a Novel Dual-Drop-off ddPCR Assay for the Simultaneous Detection of Ten Hotspots
    Stergiopoulou D; Smilkou S; Georgoulias V; Kaklamanis L; Lianidou E; Markou A
    Anal Chem; 2023 Sep; 95(37):14068-14076. PubMed ID: 37681347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
    Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
    Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
    R HC; Kumar S U; R G; Naayanan PJ; Sathiyarajeswaren P; Devi MSS; K SS; Doss C GP
    J Cell Biochem; 2023 Feb; 124(2):188-204. PubMed ID: 36563059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
    Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
    Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M; González-Farré B; Sanfeliu E; Schettini F; Conte B; Brasó-Maristany F; Rodríguez A; Martínez D; Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A
    Breast Cancer Res; 2020 May; 22(1):45. PubMed ID: 32404150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.
    Corné J; Quillien V; Callens C; Portois P; Bidard FC; Jeannot E; Godey F; Le Du F; Robert L; Bourien H; Brunot A; Crouzet L; Perrin C; Lefeuvre-Plesse C; Diéras V; de la Motte Rouge T
    Clin Chim Acta; 2023 May; 545():117366. PubMed ID: 37105452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
    Gasch C; Oldopp T; Mauermann O; Gorges TM; Andreas A; Coith C; Müller V; Fehm T; Janni W; Pantel K; Riethdorf S
    Mol Oncol; 2016 Oct; 10(8):1330-43. PubMed ID: 27491860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PIK3CA gene mutations in Chinese women with HR
    Wu SF; Wang XF; Liu YY; Xia C; Liang ZY; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1246-1250. PubMed ID: 36480834
    [No Abstract]   [Full Text] [Related]  

  • 12. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
    Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
    Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplexed assays for detection of mutations in PIK3CA.
    Board RE; Thelwell NJ; Ravetto PF; Little S; Ranson M; Dive C; Hughes A; Whitcombe D
    Clin Chem; 2008 Apr; 54(4):757-60. PubMed ID: 18375489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
    Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C
    Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
    Jacot W; Dalenc F; Lopez-Crapez E; Chaltiel L; Durigova A; Gros N; Lozano N; Lacaze JL; Pouderoux S; Gladieff L; Romieu G; Roché H; Filleron T; Lamy PJ
    Breast Cancer Res Treat; 2019 Oct; 177(3):659-667. PubMed ID: 31297647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
    Shimoi T; Hamada A; Yamagishi M; Hirai M; Yoshida M; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
    Cancer Sci; 2018 Aug; 109(8):2558-2566. PubMed ID: 29906308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.
    Lambert A; Salleron J; Lion M; Rouyer M; Lozano N; Leroux A; Merlin JL; Harlé A
    Pathol Oncol Res; 2019 Jul; 25(3):1117-1123. PubMed ID: 30426328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutation enrichment and quantitation from blood and tissue.
    Keraite I; Alvarez-Garcia V; Garcia-Murillas I; Beaney M; Turner NC; Bartos C; Oikonomidou O; Kersaudy-Kerhoas M; Leslie NR
    Sci Rep; 2020 Oct; 10(1):17082. PubMed ID: 33051521
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Tang Y; Li J; Xie N; Yang X; Liu L; Wu H; Tian C; He Y; Wang X; He Q; Hu ZY; Ouyang Q
    Aging (Albany NY); 2020 Jan; 12(2):1577-1590. PubMed ID: 31980592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.